Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

736 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.
Kuendgen A, Müller-Thomas C, Lauseker M, Haferlach T, Urbaniak P, Schroeder T, Brings C, Wulfert M, Meggendorfer M, Hildebrandt B, Betz B, Royer-Pokora B, Gattermann N, Haas R, Germing U, Götze KS. Kuendgen A, et al. Among authors: haferlach t. Oncotarget. 2018 Jun 12;9(45):27882-27894. doi: 10.18632/oncotarget.25328. eCollection 2018 Jun 12. Oncotarget. 2018. PMID: 29963245 Free PMC article. Review.
Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes.
Valent P, Hofmann WK, Büsche G, Sotlar K, Horny HP, Haase D, Haferlach T, Kern W, Bettelheim P, Baumgartner C, Sperr WR, Nösslinger T, Wimazal F, Giagounidis AA, Lübbert M, Krieger O, Kolb HJ, Stauder R, Pfeilstöcker M, Gattermann N, Fonatsch C, Aul C, Germing U. Valent P, et al. Among authors: haferlach t. Ann Hematol. 2009 Jul;88(7):607-11. doi: 10.1007/s00277-008-0673-7. Epub 2009 Jan 16. Ann Hematol. 2009. PMID: 19148644
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).
Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, Kohlmann A, Alpermann T, Yoshida K, Ogawa S, Koeffler HP, Kern W, Haferlach C, Schnittger S. Meggendorfer M, et al. Among authors: haferlach t, haferlach c. Blood. 2012 Oct 11;120(15):3080-8. doi: 10.1182/blood-2012-01-404863. Epub 2012 Aug 23. Blood. 2012. PMID: 22919025 Free PMC article.
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, Haferlach T, Schnittger S. Meggendorfer M, et al. Among authors: haferlach t, haferlach c. Leukemia. 2013 Sep;27(9):1852-60. doi: 10.1038/leu.2013.133. Epub 2013 Apr 30. Leukemia. 2013. PMID: 23628959
Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms.
Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, Ayuk F, Wolschke C, Schnittger S, Kohlmann A, Haferlach T, Kröger N. Fu Y, et al. Among authors: haferlach t. Eur J Haematol. 2014 Mar;92(3):189-94. doi: 10.1111/ejh.12223. Epub 2013 Nov 21. Eur J Haematol. 2014. PMID: 24164563
Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.
Bacher U, Haferlach T, Schnittger S, Zenger M, Meggendorfer M, Jeromin S, Roller A, Grossmann V, Krauth MT, Alpermann T, Kern W, Haferlach C. Bacher U, et al. Among authors: haferlach t, haferlach c. Br J Haematol. 2014 Mar;164(6):822-33. doi: 10.1111/bjh.12710. Epub 2013 Dec 26. Br J Haematol. 2014. PMID: 24372512 Free article.
BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.
Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C, Fasan A, Kohlmann A, Meggendorfer M, Haferlach C, Kern W, Haferlach T, Schnittger S. Weber S, et al. Among authors: haferlach t, haferlach c. Blood Cancer J. 2014 Jan 10;4(1):e173. doi: 10.1038/bcj.2013.71. Blood Cancer J. 2014. PMID: 24413067 Free PMC article.
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
Müller-Thomas C, Rudelius M, Rondak IC, Haferlach T, Schanz J, Huberle C, Schmidt B, Blaser R, Kremer M, Peschel C, Germing U, Platzbecker U, Götze K. Müller-Thomas C, et al. Among authors: haferlach t. Haematologica. 2014 Oct;99(10):e179-81. doi: 10.3324/haematol.2014.104760. Epub 2014 Jun 27. Haematologica. 2014. PMID: 24972774 Free PMC article. No abstract available.
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia.
Meggendorfer M, Haferlach T, Alpermann T, Jeromin S, Haferlach C, Kern W, Schnittger S. Meggendorfer M, et al. Among authors: haferlach t, haferlach c. Haematologica. 2014 Dec;99(12):e244-6. doi: 10.3324/haematol.2014.113159. Epub 2014 Sep 19. Haematologica. 2014. PMID: 25239264 Free PMC article. No abstract available.
736 results